What Is Visoluten? The Retinal Peptide Bioregulator Explained

Scientifically reviewed by
Dr. Ky H. Le, MD

The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.

Visoluten is a polypeptide complex isolated from bovine retinal tissue, catalogued as the A-11 bioregulator in the Khavinson peptide classification system. It belongs to a class of tissue-specific short-chain peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology and has been a subject of laboratory investigation for several decades a 2002 foundational review of the peptide bioregulator research program.

This article is intended for researchers working in ocular biology, cellular aging, and peptide bioregulation. All compounds discussed are for research use only.

What Is Visoluten?

Visoluten is the common trade name for the A-11 retinal peptide complex — a preparation of short-chain amino acid sequences derived from the retinal tissue of young bovines. The compound carries a molecular weight of up to 10 kDa and consists of multiple peptide fractions rather than a single defined sequence as described in the comprehensive review of peptide bioregulators and aging.

It occupies a specific slot within the Khavinson cytomax classification: each cytomax targets a defined organ system, and the retinal peptides were among the earliest developed under this research program. The original patent dates to 1993 (RU Patent No. 1436305), with a second patent following in 1997 (RU Patent No. 2073518).

Visoluten differs from synthetic retinal peptides such as Epitalon, which is the defined tetrapeptide Ala-Glu-Asp-Gly. While Epitalon has also been studied in retinal degeneration models, Visoluten is a multi-fraction natural complex — making it a distinct research compound with a different mechanistic profile.

How Visoluten Fits Into the Khavinson Bioregulator Research Program

The Khavinson program is one of the more extensively documented tissue-specific peptide research initiatives in the biogerontology literature, spanning roughly four decades of output from the St. Petersburg Institute of Bioregulation and Gerontology.

The foundational thesis holds that aging corresponds to a progressive decline in the synthesis of regulatory and tissue-specific peptides. When that synthesis is disrupted, organ function degrades in ways that compound over time. The hypothesis, sometimes called the peptide theory of aging, proposes that delivering exogenous peptide complexes may help restore normal gene expression patterns within their target tissues as outlined in research from the St. Petersburg Institute of Bioregulation and Gerontology.

Each organ-targeted complex in the program — including those studied for the brain (Cerluten), vascular tissue (Vesugen), and retina (Visoluten) — is understood to act by binding chromatin and influencing transcriptional activity in tissue-specific ways. For a broader overview of how these compounds are classified and studied, see BioLongevity Labs’ guide to what peptide bioregulators are.

Visoluten’s retinal specificity is a central research question. Unlike generalist antioxidant formulations, the polypeptide fractions in Visoluten are proposed to act selectively within retinal cells rather than systemically — a claim that the laboratory literature has tested in several distinct model systems.

How Researchers Study Visoluten’s Mechanism

The primary mechanistic hypothesis is that Visoluten peptide fractions, once introduced to retinal cell cultures, interact with chromatin to upregulate tissue-specific protein synthesis. The effect is posited to bypass ordinary transcription bottlenecks associated with cellular aging as described in the Khavinson peptide aging review.

The supporting evidence for this mechanism comes from two directions: organotypic culture studies and animal degeneration models.

In organotypic culture studies, retinal polypeptide complexes have been tested against cultures of retinal tissue from both young and aged animals. Research from the St. Petersburg Institute using such models found that polypeptide complexes — including the retinal preparation — increased the expression of the proliferation marker Ki-67 and reduced expression of apoptotic markers p53 and caspase-3 as reported in a 2017 study in the Bulletin of Experimental Biology and Medicine. The effect was observed across multiple organ-type cultures, with a correlation noted between regenerative intensity and the age of the source animal.

Animal degeneration models, particularly Campbell rats with hereditary retinitis pigmentosa, have been used to study retinal bioregulator effects in vivo. Studies using the related tetrapeptide Epitalon — which shares the Ala-Glu-Asp-Gly sequence proposed to be relevant to both the pineal gland and retina — found that early and sustained administration preserved the morphological structure of the retina and maintained its bioelectrical activity over a longer period compared to untreated controls as published in the Bulletin of Experimental Biology and Medicine, 2002.

What the Research Literature Examines

The published record on retinal peptide bioregulators spans approximately three decades of output, with most of the foundational studies originating from the St. Petersburg Institute research group. Here is a structured look at the key research areas.

Retinal Cell Culture Models

Organotypic culture systems have been the primary in vitro tool for studying the retinal polypeptide complex. In these models, tissue-specific peptide preparations are introduced to retinal explant cultures, and changes in cellular markers are tracked over time.

A 2017 study published in the Bulletin of Experimental Biology and Medicine examined polypeptide complexes derived from multiple tissues — including retina, blood vessels, bronchi, and kidneys — in organotypic cultures from young and old animals Ryzhak et al., 2017. The retinal complex produced measurable changes in Ki-67 expression (upregulated) and p53 and caspase-3 expression (downregulated), consistent with a shift toward cell renewal and away from apoptotic signaling. The correlation between effect intensity and donor animal age was a notable secondary finding.

Retinitis Pigmentosa Animal Models

Campbell rats, which carry a hereditary form of retinal degeneration analogous to retinitis pigmentosa, have served as a widely used in vivo model for retinal bioregulator research.

In animal research, the tetrapeptide Epitalon — whose sequence the Khavinson program also associates with retinal transcriptional pathways — was studied for its effect on retinal morphology and electrical activity in this model. Administration beginning at birth preserved the morphological structure of the retina and increased its bioelectrical activity relative to control groups Khavinson et al., 2002, Bulletin of Experimental Biology and Medicine. A subsequent study found that maternal administration of the peptide before and during pregnancy extended this protective window — with retinal functional integrity preserved approximately twice as long compared to postnatal-only administration Khavinson et al., 2003, Bulletin of Experimental Biology and Medicine.

Clinical Observational Studies in Retinal Disease Contexts

The St. Petersburg research group also published clinical data on peptide bioregulator use in retinal disease contexts. A study examining 104 patients with diabetic retinopathy who received bioregulatory therapy — including the retinal preparation retinalamine alongside other organ-targeted peptide complexes — reported that 90% of cases showed improvement in visual acuity and ophthalmoscopic findings Trofimova and Khavinson, 2001, Vestn Oftalmol. Improvements included resolution of hemorrhages, reduction in macular edema, and normalization of retinal blood flow. No adverse changes in clinical picture were recorded across any of the cases.

A separate controlled clinical study using Epitalon in patients with pigmented retinal degeneration found a positive clinical effect in 90% of cases, with electroretinography confirming improved bioelectric and functional activity of the retina Khavinson et al., 2002, Neuro Endocrinol Lett. The authors proposed that the tetrapeptide participates in transcriptional mechanisms shared between the epiphysis and retina — pointing to the embryological connection between these two structures.

Visoluten in the Context of Other Ocular Research Peptides

Visoluten is not the only compound researchers investigate in ocular biology contexts. BioLongevity Labs’ article on peptides for ocular and retinal research covers the broader landscape of peptides studied in visual system contexts, including structural and vascular-support compounds.

Within the bioregulator category specifically, the retinal complex is typically studied alongside the vascular bioregulator (Ventfort/A-3) and the cerebral bioregulator (Cerluten/A-5), given that retinal health involves microvascular integrity as well as neural signaling. Researchers interested in the neural peptide side of this picture may also consult BioLongevity Labs’ coverage of Cortagen, the cortical peptide bioregulator, which sits in the same research program.

The common thread across these compounds is tissue specificity. Where antioxidant or anti-inflammatory compounds act broadly, Khavinson-program bioregulators are studied for selective action in their respective target tissues — a mechanistic distinction that continues to drive laboratory interest in this compound class.

Visoluten In Vitro Research Applications

Research Application	Relevant Model System	Key Variables Examined
Retinal cell renewal markers	Organotypic culture (young vs. aged tissue)	Ki-67 upregulation, p53/caspase-3 downregulation
Hereditary retinal degeneration models	Campbell rat (retinitis pigmentosa analog)	ERG activity, morphological structure preservation
Ocular peptide deficiency modeling	Cell culture	Protein synthesis normalization, chromatin interaction
Age-related retinal decline research	In vivo/organotypic combined	Bioelectric activity, tissue integrity over time
Peptide specificity and tissue targeting	Comparative organotypic panels	Organ-specific vs. non-specific peptide response

Where to Source Visoluten for Research

For laboratories sourcing the A-11 retinal peptide complex, documentation standards matter significantly for experimental reproducibility.

BioLongevity Labs supplies BioRetina (Visoluten A-11) with triple third-party COA documentation covering HPLC purity verification, LC-MS molecular identity confirmation, and sterility and endotoxin testing. All batches are manufactured in a U.S. GMP-certified facility and ship with a full analytical dossier. Researchers can review COA results before purchase. For guidance on reading peptide COAs, BioLongevity Labs’ COA quality guide is a practical reference.

All BioLongevity Labs compounds, including Visoluten, are supplied strictly for research use.

References

[1] Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12374906/

[2] Ryzhak AP, Chalisova NI, Lin’kova NS, Nichik TE, Dudkov AV, Kolchina NV, Ryzhak GA, Khalimov RI. Effect of Polypeptides on Cell Proliferation and Apoptosis during Aging. Bull Exp Biol Med. 2017;162(4):534-538. doi:10.1007/s10517-017-3655-8

[3] Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-8. https://pubmed.ncbi.nlm.nih.gov/12195242/

[4] Khavinson VKh, Razumovsky MI, Trofimova SV, Razumovskaya AM. Retinoprotective effect of Epithalon in Campbell rats of various ages. Bull Exp Biol Med. 2003;135(5):495-8. doi:10.1023/A:1024931812822

[5] Khavinson VKh, Razumovskii MI, Trofimova SV, Grigor’yan RA, Chaban TV, Oleinik TL, Razumovskaya AM. Effect of epithalon on age-specific changes in the retina in rats with hereditary pigmentary dystrophy. Bull Exp Biol Med. 2002;133(1):87-9. doi:10.1023/A:1015125031829

[6] Trofimova SV, Khavinson VKh. Effectiveness of bio-regulators in the treatment of diabetic retinopathy. Vestn Oftalmol. 2001;117(3):11-4. https://pubmed.ncbi.nlm.nih.gov/11521426/